News

PharmaEssentia Corporation (Stock Code: 6446) proudly announces its consecutive triumph at the 2023 Taiwan Corporate Sustainability Awards (TCSA) and Global Corporate Sustainability Awards (GCSA), securing the "Platinum Award" for the Chinese report in the Healthcare category and the "Bronze Award" for the Global Sustainability Award in the English report. This achievement marks the company's continuous success in the "Taiwan Corporate Sustainability Awards," showcasing its unwavering commitment to sustainability and excellence.   

Sustainable Development – A Global Imperative    

Sustainable development has become a focal point for the international community and global businesses, serving as a crucial reference indicator for global investment institutions. The "Taiwan Corporate Sustainability Awards" (TCSA)  and the "Global Corporate Sustainability Awards" (GCSA) by Taiwan Institute for Sustainable Energy (TAISE) to commend companies with the most complete and transparent disclosure of sustainable development information.   

PharmaEssentia's repeated success in securing top honors for consecutive years highlights the company's commitment to providing comprehensive and transparent information in its sustainability reports, garnering high praise from the professional judging panel.   

SDG3 as Core Vision   

The United Nations' Sustainable Development Goals (SDGs) consist of 17 core objectives, with PharmaEssentia placing a deep emphasis on SDG3 – "Good Health and Well-being" – as its core sustainability vision. The company is dedicated to meeting the urgent needs of patients by investing in the research, development, clinical trials, production, and marketing of new drugs. PharmaEssentia aims to develop the best new drugs of its kind, providing them to patients worldwide and establishing itself as a comprehensive international biotech company rooted in Taiwan.  

Exemplary ESG Practices   

In its pursuit of sustainable action, PharmaEssentia strives to provide high-quality and meaningful Environmental, Social, and Governance (ESG) information in its reports. The company not only adopts guidelines and frameworks specifically designed for the international biopharmaceutical industry to ensure that its reports accurately reflect industry characteristics, but it also introduces third-party independent organizations to audit and verify the accuracy and reliability of the reports. Diverse communication channels are set up to assist investors and stakeholders in understanding the company's ESG risk management and performance results comprehensively.   

International Recognition and Ratings   

PharmaEssentia has completed the Corporate Sustainability Assessment (CSA) by S&P Global for three consecutive years, elevating its rating to the 98th percentile globally in the biotech industry. The company also achieved a BB rating in the MSCI ESG assessment, attracting attention for its market size, liquidity, and trading volume. This recognition signifies the relentless efforts of the company and her Sustainability Development Center in the ESG field, as well as the success of enhancing information disclosure transparency. This has led to increased evaluations from both domestic and international investment institutions.   

For further information:

Please visit PharmaEssentia's Sustainable ESG website at http://www.pharmaessentia-esg.com  

 or contact the Corporate Sustainability Development Center at CSR-ESG@pharmaessentia.com

Media inquiries may be directed to Ms. Shu-Fen Li, Senior Director, at +886-2-26557688 (ext. 7839).